

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

CD25 (IL-2 Receptor ?)

RRID:AB_2738803

Type: Antibody

Proper Citation

BD Biosciences Cat# 564424, RRID:AB_2738803

Antibody Information

URL: http://antibodyregistry.org/AB_2738803

Proper Citation: BD Biosciences Cat# 564424, RRID:AB_2738803

Target Antigen: CD25 (IL-2 Receptor ?)

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD25 (IL-2 Receptor ?)

Description: This monoclonal targets CD25 (IL-2 Receptor ?)

Target Organism: mouse

Clone ID: PC61

Antibody ID: AB_2738803

Vendor: BD Biosciences

Catalog Number: 564424

Record Creation Time: 20250819T235820+0000

Record Last Update: 20250820T065846+0000

Ratings and Alerts

No rating or validation information has been found for CD25 (IL-2 Receptor ?).

No alerts have been found for CD25 (IL-2 Receptor ?).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yao Y, et al. (2025) Short-chain fatty acids regulate T cell heterogeneity to alleviate recurrent spontaneous abortion. *British journal of pharmacology*.

Cai S, et al. (2025) Methionine regulates maternal-fetal immune tolerance and endometrial receptivity by enhancing embryonic IL-5 secretion. *Cell reports*, 44(2), 115291.

Cai HM, et al. (2025) DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis. *Cell reports*, 44(9), 116237.

Oh JH, et al. (2025) Naturalized immune responses are stable over years in a colony of laboratory mice with wild-derived microbiota. *Immunity*, 58(9), 2305.

Corriveau J, et al. (2025) Inhibition of PAK2 in endothelial cells suppresses tumor angiogenesis and promotes immune sensitization through CXCL10. *Cell reports*, 45(1), 116840.

He C, et al. (2024) UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. *Molecular cell*, 84(6), 1120.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. *Cell reports*, 43(5), 114141.

Wang Q, et al. (2024) Benzosciptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. *Cell reports. Medicine*, 5(2), 101357.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. *Nature communications*, 14(1), 2859.

Ajouaou Y, et al. (2022) The oxygen sensor prolyl hydroxylase domain 2 regulates the in vivo suppressive capacity of regulatory T cells. *eLife*, 11.

Yang SJ, et al. (2020) Activation of M1 Macrophages in Response to Recombinant TB Vaccines With Enhanced Antimycobacterial Activity. *Frontiers in immunology*, 11, 1298.

Oldenhove G, et al. (2018) PD-1 Is Involved in the Dysregulation of Type 2 Innate Lymphoid Cells in a Murine Model of Obesity. *Cell reports*, 25(8), 2053.